Dr. Mimi Yeh of Lumosa Therapeutics (Lumosa) presented the recent advancement in the preclinical research of LT3001 in the oral session at the 13th International Symposium on Thrombolysis Thrombectomy and Acute Stroke Therapy (TTST), held in Kobe, Japan (October 30th and November 1, 2016).  TTST is one of the few international medical conferences focusing on stroke research. Lumosa was honored to be the only drug development company invited to present and the presentation titled “Study of a novel small molecule, LT3001, in a thromboembolic stroke model in non-human primates" (http://www2.convention.co.jp/ttst2016/program.html), gained much attention from the scientists and physicians attending TTST.  There has not been a new drug on the market for the treatment of acute ischemic stroke for almost 20 years since tPA was approved in 1996.  


Lumosa also held a very successful advisory meeting to discuss clinical development plans for LT3001.  The advisors were very excited about LT3001 and expressed their strong interest to work with Lumosa in the future. Lumosa plans to submit Investigational New Drug (IND) application for LT3001 to the US FDA in 2017.